Sanket Basida

Sanket Basida

Auto-generated profile, based on publicly available information

Sanket Basida

Department of Gastroenterology and Hepatology, The University of Kansas Health System, Kansas City, Kansas

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 July 2022 in International Journal of Heart Failure
Verified
Journal Article
Open access
PDF file
KGKarthik Gangu
Karthik Gangu
ABAniesh Bobba
Aniesh Bobba
HCHarleen Kaur Chela
Harleen Kaur Chela
SASindhu Avula
Sindhu Avula
SBSanket Basida
Sanket Basida
NYNeha Yadav
Neha Yadav
Gangu K, et al. Int J Heart Fail. 2022 Jul;4:e16. https://doi.org/10.36628/ijhf.2022.0002

20 July 2026 in Gastro Hep Advances
Verified
Journal Article
Open access
SBSanket Basida
Sanket Basida
MYMuhammad Nadeem Yousaf
Muhammad Nadeem Yousaf
CEChukwunonso Ezeani
Chukwunonso Ezeani
DNDrew Nannini
Drew Nannini
PZParit Zalavadia
Parit Zalavadia
STShyam Thakkar
Shyam Thakkar
Radiofrequency ablation (RFA) is a proven therapy for solid organ tumors. Endoscopic ultrasound-guided RFA (EUS-RFA) is a less invasive, emerging technique that may serve as an alternative to surgical resection for unresectable pancreatic tumors (UPT). However, its efficacy, safety, and clinical outcomes in tumor subgroups remain unclear. This systematic review and meta-analysis evaluate the efficacy, clinical, and technical success (TS) of EUS-RFA for UPT. A comprehensive search of PubMed, Web of Science, Embase, Cochrane, and Clinicaltrials.gov (as of April 2025) identified studies on EUS-RFA and pancreatic tumors. Primary outcomes were TS, defined as probe placement and ablation regardless of outcome, and clinical success (CS), defined as symptomatic improvement or tumor size reduction with necrosis. Secondary outcomes included adverse events and efficacy for tumor subtypes. A pooled analysis using random-effect modeling was performed using the metafor R package. Seventeen studies involving 168 patients (52.38% female) and 182 tumors were included. Tumors included pancreatic neuroendocrine tumors (106, 58.24%), pancreatic ductal adenocarcinomas (49, 26.92%), and others. Tumors were located primarily in the body, neck, or tail (54.02%). Average ablation sessions per patient were 1.1. Pooled TS and CS rates were 89% and 84%, respectively. Nonfunctional neuroendocrine tumors and mixed type showed the highest CS rate (91%). The most common adverse event included abdominal pain (6.5%) and hyperamylasemia (3.6%). EUS-RFA is a promising, safe modality for managing UPT, with high TS (89%) and CS (84%) rates. Larger clinical trials are needed to confirm safety, outcomes, and survival benefits for pancreatic cancer subtypes.